ME-344 free base · Synonyms: ME 344 · ME344

ME-344 is a mitochondrial Heme oxygenase 1 inhibitor.

For research use only. Not for human or veterinary use.

Target Heme Oxygenase (HO) Reactive Oxygen Species (ROS) Mitochondrial Metabolism Microtubule/Tubulin Caspase Apoptosis

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

ME-344 structure

CAS No.: 1374524-68-1

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
25 mg	USD 562.00	BP-01218-25mg	In stock	Get quote
50 mg	USD 862.00	BP-01218-50mg	In stock	Get quote
100 mg	USD 1,362.00	BP-01218-100mg	In stock	Get quote
250 mg	USD 1,958.00	BP-01218-250mg	In stock	Get quote
500 mg	USD 2,762.00	BP-01218-500mg	In stock	Get quote
1 g	Inquire	BP-01218-1g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

ME-344 is a mitochondrial Heme oxygenase 1 (HO-1) inhibitor. ME-344 specifically binds and alters HO-1 structure, and increases HO-1 translocation from the rough endoplasmic reticulum to mitochondria, but only in drug-sensitive cells (such as H460 and SHP-77 cells). ME-344 decreases mitochondrial ATP production and induces ROS, with subsequent disruption of redox homeostasis and mitochondrial function. ME-344 has significant antitumor activity, and can be used for cancers like breast cancer research .

Biological activity

In Vitro ME-344 (24 h) induces apoptosis in sensitive H460 and SHP-77 human lung cancer cells via activation of Caspase 3 and subsequent cleavage of PARP. ME-344 (10-10000 nM; 72 h) is cytotoxic to NB4, U937, K562, OCI-AML2, KG1a, HL-60, and TEX leukemia cell lines with IC50 values ranging from 70 to 260 nM after 72 h of treatment. ME-344 (10 μM) potently inhibits tubulin polymerization in a cell-free biochemical assay. ME-344 (8 h) suppresses the de novo purine biosynthesis pathway in MV4-11 AML cells after 8 h of treatment, significantly reducing levels of AICAR and IMP. In Vivo ME-344 (50-100 mg/kg; i.p.; every other day; 11 days) produces dose-dependent anti-tumor efficacy in a leukemia xenograft mouse model.

Identifiers

SMILES: OC1=CC=C2[C@H](C3=CC=C(O)C=C3)[C@H](C4=CC=C(O)C=C4)COC2=C1C
InChIKey: QVCAATSEPLQVBX-FPOVZHCZSA-N

Specifications

MW (average): 348.3918
Formula: C₂₂H₂₀O₄
CAS No.: 1374524-68-1
Physical state: Solid
Color: white to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder 4℃ 2 years, protect from light; In solvent -20℃ 1 month;

Solubility

soluble in DMSO

Documents

References

[1]. Zhang L, et al. Isoflavone ME-344 Disrupts Redox Homeostasis and Mitochondrial Function by Targeting Heme Oxygenase 1. Cancer Res. 2019;79(16):4072-4085.

[2]. Jeyaraju DV, et al. A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia. Oncotarget. 2016;7(31):49777-49785.

[3]. Quintela-Fandino M, et al. Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer. Clin Cancer Res. 2020;26(1):35-45.

[4]. Hurrish K H, et al. A novel isoflavone, ME-344, enhances venetoclax antileukemic activity against AML via suppression of oxidative phosphorylation and purine biosynthesis[J]. Blood, 2021, 138: 2238.

Same target

Search Heme Oxygenase (HO)

Same research area

Search Cancer